Handelsbanken Fonder Ab I Mab Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$4.01 - $12.34 $421,050 - $1.3 Million	-105,000 Reduced 46.56%	120,502 $483,000
Q1 2022 May 11, 2022	SELL	$12.54 - $46.93 $376,200 - $1.41 Million	-30,000 Reduced 11.74%	225,502 $3.66 Million
Q3 2021 Nov 10, 2021	BUY	$57.18 - $84.43 $2 Million - $2.96 Million	35,000 Added 15.87%	255,502 $18.5 Million
Q2 2021 Aug 03, 2021	SELL	$47.86 - $83.95 $335,020 - $587,650	-7,000 Reduced 3.08%	220,502 $18.5 Million
Q1 2021 Apr 29, 2021	BUY	$44.38 - $63.97 $5.44 Million - $7.84 Million	122,502 Added 116.67%	227,502 $11 Million

Q4 2020 Feb 11, 2021	BUY	$32.94 - $47.15 $3.46 Million - $4.95 Million	105,000 New	105,000 $4.95 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.